Skip to main content

Tiam1/Vav2-Rac1 axis: A tug-of-war between islet function and dysfunction.

Citation
Kowluru, A. “Tiam1/Vav2-Rac1 Axis: A Tug-Of-War Between Islet Function And Dysfunction.”. Biochemical Pharmacology, pp. 9-17.
Center University of Michigan
Author Anjaneyulu Kowluru
Keywords G proteins, Glucotoxicity, islet β-cell, Rac1, Tiam1, Vav2
Abstract

Glucose-stimulated insulin secretion [GSIS] from the islet β-cell involves a well-orchestrated interplay between metabolic and cationic events. It is well established that intracellular generation of adenine and guanine nucleotide triphosphates [e.g., ATP and GTP] represents one of the requisite signaling steps in GSIS. The small molecular mass GTP-binding proteins [G-proteins; e.g., Rac1 and Cdc42] have been shown to regulate islet β-cell function including actin cytoskeletal remodeling and fusion of insulin granules with the plasma membrane for GSIS to occur. In this context, several regulatory factors for these G-proteins have been identified in the pancreatic β-cell; these include guanine nucleotide exchange factors [GEFs] and guanine nucleotide dissociation inhibitors [GDI]. Recent pharmacological and molecular biological evidence identified Tiam1 and Vav2 as GEFs for Rac1 in promoting physiological insulin secretion. Paradoxically, emerging evidence in multiple cell types, including the islet β-cell, suggests key roles for Rac1 in the onset of cellular dysfunction under conditions of metabolic stress and diabetes. Furthermore, functional inactivation of either Tiam1 or Vav2 appears to attenuate sustained activation of Rac1 and its downstream signaling events [activation of stress kinases] under conditions of metabolic stress. Together, these findings suggest both "friendly" and "non-friendly" roles for Tiam1/Vav2-Rac1 signaling axis in islet β-cell in health and diabetes. Our current understanding of the field and the knowledge gaps that exist in this area of islet biology are heighted herein. Furthermore, potential caveats in the specificity and selectivity of pharmacological inhibitors that are available currently are discussed in this Commentary.

Year of Publication
2017
Journal
Biochemical pharmacology
Volume
132
Number of Pages
9-17
Date Published
12/2017
ISSN Number
1873-2968
DOI
10.1016/j.bcp.2017.02.007
Alternate Journal
Biochem. Pharmacol.
PMID
28202288
PMCID
PMC5382093
Download citation